0000892251-16-000213.txt : 20160324 0000892251-16-000213.hdr.sgml : 20160324 20160324162245 ACCESSION NUMBER: 0000892251-16-000213 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20160322 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Completion of Acquisition or Disposition of Assets ITEM INFORMATION: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20160324 DATE AS OF CHANGE: 20160324 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MERIDIAN BIOSCIENCE INC CENTRAL INDEX KEY: 0000794172 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 310888197 STATE OF INCORPORATION: OH FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-14902 FILM NUMBER: 161527328 BUSINESS ADDRESS: STREET 1: 3471 RIVER HILLS DR CITY: CINCINNATI STATE: OH ZIP: 45244 BUSINESS PHONE: 5132713700 MAIL ADDRESS: STREET 1: 3471 RIVER HILLS DRIVE CITY: CINCINNATI STATE: OH ZIP: 45244 FORMER COMPANY: FORMER CONFORMED NAME: MERIDIAN DIAGNOSTICS INC DATE OF NAME CHANGE: 19920703 8-K 1 form8k032416.htm FORM 8-K
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 22, 2016
MERIDIAN BIOSCIENCE, INC.
(Exact name of registrant as specified in its charter)

Ohio
  
0-14902
  
31-0888197
(State or other jurisdiction of incorporation)
  
(Commission File Number)
 
  
(IRS Employer Identification No.)

3471 River Hills Drive, Cincinnati, Ohio
45244
(Address of principal executive offices)
(Zip Code)

Registrant's telephone number, including area code (513) 271-3700
 
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 ☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 ☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 ☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 ☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 1.01. Entry into a Material Definitive Agreement.
Merger Agreement
Effective March 24, 2016, Meridian Bioscience, Inc., an Ohio corporation ("Meridian" or the "Company"), Mariner Merger Sub, Inc., a Delaware corporation and a direct wholly-owned subsidiary of the Company ("Sub"), Magellan Biosciences, Inc., a Delaware corporation ("Magellan"), and Ampersand 2006 Limited Partnership, a Delaware limited partnership in its capacity as Stockholder Representative (the "Stockholder Representative"), entered into an agreement and plan of merger (the "Merger Agreement") and consummated the transactions contemplated by it, including the acquisition of all issued and outstanding shares of common stock of Magellan. Pursuant to the Merger Agreement, Sub merged with and into Magellan (the "Merger") and Magellan is the surviving corporation and became the Company's wholly-owned subsidiary. The Merger Agreement required Meridian to make an upfront cash payment of approximately $66 million subject to a working capital adjustment. $875,000 of this amount will be held in escrow for up to twelve months.
This summary of the Merger Agreement is included solely to provide investors with information regarding the terms of the Merger Agreement. It is not intended to provide factual information about the parties or any of their respective subsidiaries or affiliates. Investors are cautioned that the representations, warranties and covenants included in the Merger Agreement were made by Magellan, the Company and Sub to each other. These representations, warranties and covenants were made as of specific dates and only for purposes of the Merger Agreement and are subject to important exceptions and limitations, including a contractual standard of materiality that may be different from that generally relevant to investors, and are qualified by information disclosed in the Company's public filings as well as in confidential disclosure schedules that the parties exchanged in connection with the execution of the Merger Agreement. In addition, the representations and warranties may have been included in the Merger Agreement for the purpose of allocating risk between Magellan, the Company and Sub rather than to establish matters as facts. The representations and warranties contained in the Merger Agreement are solely for the benefit of the parties to the Merger Agreement. Investors are not third-party beneficiaries under the Merger Agreement and in reviewing the representations, warranties and covenants contained in the Merger Agreement or any descriptions thereof in this summary, it is important to bear in mind that such representations, warranties and covenants or any descriptions were not intended by the parties to the Merger Agreement to be characterizations of the actual state of facts or condition of Magellan, the Company or any of their respective subsidiaries or affiliates. Moreover, information concerning the subject matter of the representations, warranties and covenants may change after the date of the Merger Agreement, which subsequent information may or may not be fully reflected in the Company's public disclosures. For the foregoing reasons, the representations, warranties and covenants or any descriptions of those provisions should not be read alone and should instead be read in conjunction with the other information contained in the reports, statements and filings that the Company publicly files with the SEC.
Employment Agreement
Effective March 24, 2016 the Company and Amy Winslow entered into an Executive Employment Agreement (the "Employment Agreement"). Ms. Winslow was the President and Chief Executive Officer of Magellan prior to the Merger. Pursuant to the Employment Agreement Ms. Winslow will serve as an Executive Vice President of the Company and will remain as the President and Chief Executive Officer of Magellan as the Company's wholly-owned subsidiary. The initial term of the Employment Agreement is three years and is subject to automatic extension. Under the Employment Agreement Ms. Winslow will receive an annual base salary of $330,000 and is entitled to cash bonus payments under the Company's Corporate Incentive Plan of up to 120% of her base salary upon the achievement of certain earnings targets and individual performance goals. The Employment Agreement also grants Ms. Winslow under the Company's 2012 Stock Incentive Plan 10,000 stock options (subject to three year pro rata vesting), 5,000 time-based restricted stock units (subject to three year cliff vesting) and 5,000 performance-based restricted stock units (subject to three year pro rata vesting).
The Employment Agreement sets forth confidentiality, non-competition, non-solicitation, benefit and severance provisions. It provides for a payment equal to one times Ms. Winslow's  annual base salary (plus any salary earned but not paid) and annual performance bonus if she is terminated by the Company without Cause or if Ms. Winslow terminates employment for Good Reason.
Item 2.01. Completion of Acquisition or Disposition of Assets.
The information set forth under "Merger Agreement" in Item 1.01 is incorporated herein by reference in its entirety.
Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.
Effective March 22, 2016, the Company entered into the Sixth Amendment to Loan and Security Agreement (the "Sixth Amendment") by and among Fifth Third Bank, an Ohio banking corporation (the "Bank"), Meridian Bioscience Corporation, an Ohio corporation ("MBC"), Omega Technologies, Inc., an Ohio corporation ("Omega"), Meridian Life Science, Inc., a Maine corporation ("MLS"), and Bioline USA, Inc., a Massachusetts corporation ("Bioline").  MBC, Omega, MLS and Bioline are subsidiaries of Meridian and, collectively with Meridian, are referred to herein as the "Borrowers." The Sixth Amendment provides to the Borrowers a $60 million five-year term loan requiring quarterly principal payments with interest at a variable rate tied to LIBOR and a balloon payment of $37.5 million at the end of five years. The Company and the Bank also entered into an interest rate swap that effectively converts the variable interest rate on the five-year term loan to a fixed rate. The proceeds of the loan are being used for the acquisition of Magellan as described above. The obligations under the Sixth Amendment are secured by substantially all of the Company's assets.
The foregoing descriptions of the Merger Agreement, Employment Agreement and Sixth Amendment do not purport to be complete and are qualified in their entirety by reference to the Merger Agreement, Employment Agreement and Sixth Amendment, respectively, which will be filed as exhibits to the Company's next Quarterly Report on Form 10-Q and incorporated by reference herein.
Item 8.01. Other Events.
On March 24, 2016, the Company issued a press release announcing the Merger Agreement. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
The information contained in Item 8.01 to this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing by the Company under the Exchange Act.

Cautionary Statement Regarding Forward-Looking Statements
Certain statements in this communication regarding the acquisition of Magellan by Meridian, including any statements regarding the synergies, benefits and opportunities of the transaction, future opportunities for the combined company and products, future financial performance and any other statements regarding Meridian's and Magellan's future expectations, beliefs, plans, objectives, financial conditions, assumptions or future events or performance that are not historical facts are "forward-looking" statements made within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words "anticipate," "believe," "ensure," "expect," "if," "intend," "estimate," "probable," "project," "forecasts," "predict," "outlook," "aim," "will," "could," "should," "would," "potential," "may," "might," "anticipate," "likely," "plan," "positioned," "strategy," and similar expressions, and the negative thereof, are intended to identify forward-looking statements.
All forward-looking information is subject to numerous risks and uncertainties, many of which are beyond the control of Meridian, that could cause actual results to differ materially from the results expressed or implied by the statements. These risks and uncertainties include, but are not limited to: the diversion of management time on transaction-related issues; ability to successfully integrate the businesses; risk that the transaction and its announcement could have an adverse effect on Magellan's ability to retain customers and retain and hire key personnel; the risk that any potential synergies from the transaction may not be fully realized or may take longer to realize than expected; and risks inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable and competitive products. In addition, forward-looking statements may also be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. The forward-looking statements contained in this communication may become outdated over time. Meridian does not assume any responsibility for updating any forward-looking statements. Additional information concerning these and other factors can be found in Meridian's filings with the SEC and available through the SEC's Electronic Data Gathering and Analysis Retrieval system at www.sec.gov, including Meridian's most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The foregoing list of important factors is not exclusive. Meridian assumes no obligation to update or revise any forward-looking statements as a result of new information, future events or otherwise, except as may be required by law. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof.
Item 9.01. Financial Statements and Exhibits.
(a) Financial Statements of Businesses Acquired: The financial statements required to be filed under this Item 9 shall be filed by an amendment to this Form 8-K not later than 71 days after the date this Current Report on Form 8-K is required to be filed.
(b) Pro Forma Financial Information: The pro forma financial information required to be filed under this Item 9 shall be filed by an amendment to this Form 8-K not later than 71 days after the date this Current Report on Form 8-K is required to be filed.
 
(d)
Exhibits
 
Exhibit No.
Description
   
 
99.1
Press Release of the Company dated March 24, 2016.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


   
MERIDIAN BIOSCIENCE, INC.
     
Date:  March 24, 2016
  
By: /s/  Melissa A. Lueke
   
Melissa A. Lueke
   
Executive Vice President and Chief Financial Officer
   
(Principal Financial and Accounting Officer)
EX-99.1 2 form8k032416_ex99.htm PRESS RELEASE OF THE COMPANY DATED MARCH 24, 2016.

EXHIBIT 99.1

INFORMATION
.




For Immediate Release
March 24, 2016
Contact: 513.271.3700
John A. Kraeutler, Chief Executive Officer


MERIDIAN BIOSCIENCE ACQUIRES MAGELLAN DIAGNOSTICS, INC.


CINCINNATI, March 24, 2016 (GLOBE NEWSWIRE)—Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) announced today that it has completed the acquisition of Magellan Biosciences, Inc. and its wholly owned subsidiary Magellan Diagnostics, Inc. Headquartered in Billerica, Massachusetts (near Boston), Magellan pioneered the engineering, development and manufacturing of FDA-cleared products for the testing of blood to diagnose lead poisoning in children and adults.

Today, Magellan is the leading provider of point-of-care lead testing systems with placements in more than 6,500 physician offices and clinics nationwide.  Its position in pediatric offices is particularly strong.  LeadCare® II, the only CLIA-waived lead testing system, enables physician practices to enhance the quality of care, improve patient compliance and convenience, and reduce costs.  Magellan's LeadCare Ultra® and Plus® systems are designed for use in hospitals and reference labs.

Magellan has a robust product development pipeline and plans to introduce a third generation platform that will include a menu of additional high value CLIA-waived pediatric tests including, but not limited to, lead testing.  Magellan's talented team of executives and employees led by Amy Winslow, President and Chief Executive Officer of Magellan, will continue to manage the business, which will remain in its current location and facility.

From a strategic perspective, the acquisition of Magellan provides (i) an important point-of-care capability, (ii) ready-made access and expansion of certain of Meridian's products into the pediatric market, (iii) expansion of Magellan's products into international markets where Meridian has a presence, (iv) opportunities within Meridian's hospital market as hospitals acquire physician office practices, and (v) a new growth driver as the importance of lead testing and remediation in the United States and global community becomes better understood.

Magellan was acquired from an investor group including Ampersand Capital Partners as the majority owner, along with Abingworth, Tekla Capital Management and Boston Community Venture Fund.  Magellan sales for 2015 were $16 million and the business is growing and profitable. Meridian expects Magellan to be accretive to earnings per share during the second half of calendar 2017.  Meridian will finance the purchase price of $66 million using a combination of cash on hand and a $60 million five-year term loan.  Meridian remains conservatively capitalized and in a position to maintain its indicated annual cash dividend rate, fund expected growth requirements, and pursue additional acquisitions.

John A. Kraeutler, Chairman and Chief Executive Officer of Meridian, commented, "A key underpinning of our diagnostic growth strategies has been to address 'test and treat' opportunities by applying highly accurate and simple-to-use tests for rapid diagnoses, thereby enabling appropriate treatment.  Because elevated lead levels can cause serious developmental impairment, especially in young children, the need for broad testing and fast remediation of the contaminated environment is acute.  Magellan has maintained a clear focus on developing and marketing test systems that are well recognized for their accuracy and ease-of-use.  Further, the Magellan test systems are now in use by more than 10,000 pediatricians, primarily in the U.S.  We believe that there is excellent growth potential in Magellan Diagnostics on its own, both with the existing products and the pending new product pipeline.  Further, we believe that Meridian and Magellan can leverage their complementary but separate customer channels both in the U.S. and global markets.  From the beginning of this process, we have been impressed by the quality of the Magellan team.  We believe that the respective company cultures will align very well and, it is our intention to allow Magellan to remain largely autonomous while working closely on strategic opportunities that maximize the strengths of each.  We welcome each member of Magellan into the Meridian Bioscience family of companies!"

Amy M. Winslow, President and Chief Executive Officer of Magellan, commented, "By joining forces with Meridian Bioscience, Magellan Diagnostics will better achieve our mission of identifying and protecting the millions of people – primarily children – at risk from the devastating, lifelong effects of lead.  Our proprietary sensor-based platform has been refined over the course of a decade and offers unparalleled simplicity as well as the design flexibility to enable menu expansion. Meridian understands the potential of our platform and of our pediatric footprint; the synergies between Meridian and Magellan were clear from the outset, especially our mutual dedication to delivering unique tests that simplify the diagnostic process. Together, we will have a larger presence in both hospital laboratories and in physician offices, both in the U.S. and abroad, to bring our respective products to more patients who need them."

FORWARD-LOOKING STATEMENTS
The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements.  Except for historical information, this report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, which may be identified by words such as "estimates", "anticipates", "projects", "plans", "seeks", "may", "will", "expects", "intends", "believes", "should" and similar expressions or the negative versions thereof and which also may be identified by their context.  All statements that address operating performance or events or developments that Meridian expects or anticipates will occur in the future, including, but not limited to, statements relating to per share diluted earnings and revenue, are forward-looking statements.  Such statements, whether expressed or implied, are based upon current expectations of the Company and speak only as of the date made.  Specifically, Meridian's forward-looking statements are, and will be, based on management's then-current views and assumptions regarding future events and operating performance.  Meridian assumes no obligation to publicly update or revise any forward-looking statements even if experience or future changes make it clear that any projected results expressed or implied therein will not be realized.  These statements are subject to various risks, uncertainties and other factors that could cause actual results to differ materially, including, without limitation, the following:

Meridian's continued growth depends, in part, on its ability to introduce into the marketplace enhancements of existing products or new products that incorporate technological advances, meet customer requirements and respond to products developed by Meridian's competition, and its ability to effectively sell such products.  While Meridian has introduced a number of internally developed products, there can be no assurance that it will be successful in the future in introducing such products on a timely basis.  Meridian relies on proprietary, patented and licensed technologies, and the Company's ability to protect its intellectual property rights, as well as the potential for intellectual property litigation, would impact its results.  Ongoing consolidations of reference laboratories and formation of multi-hospital alliances may cause adverse changes to pricing and distribution.  Recessionary pressures on the economy and the markets in which our customers operate, as well as adverse trends in buying patterns from customers, can change expected results.  Costs and difficulties in complying with laws and regulations, including those administered by the United States Food and Drug Administration, can result in unanticipated expenses and delays and interruptions to the sale of new and existing products.  The international scope of Meridian's operations, including changes in the relative strength or weakness of the U.S. dollar and general economic conditions in foreign countries, can impact results and make them difficult to predict.  One of Meridian's growth strategies is the acquisition of companies and product lines.  There can be no assurance that additional acquisitions will be consummated or that, if consummated, will be successful and the acquired businesses will be successfully integrated into Meridian's operations.  There may be risks that acquisitions may disrupt operations and may pose potential difficulties in employee retention and there may be additional risks with respect to Meridian's ability to recognize the benefits of acquisitions, including potential synergies and cost savings or the failure of acquisitions to achieve their plans and objectives.  Meridian cannot predict the possible impact of U.S. health care legislation enacted in 2010 – the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act – and any modification or repeal of any of the provisions thereof, and any similar initiatives in other countries on its results of operations.  Efforts to reduce the U.S. federal deficit, breaches of Meridian's information technology systems and natural disasters and other events could have a materially adverse effect on Meridian's results of operations and revenues.  In addition to the factors described in this paragraph, Part I, Item 1A Risk Factors of our Form 10-K contains a list and description of uncertainties, risks and other matters that may affect the Company.

Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic test kits, purified reagents and related products and offers biopharmaceutical enabling technologies. Utilizing a variety of methods, these products and diagnostic tests provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as gastrointestinal, viral and respiratory infections. Meridian's diagnostic products are used outside of the human body and require little or no special equipment. The Company's products are designed to enhance patient well-being while reducing the total outcome costs of health care. Meridian has strong market positions in the areas of gastrointestinal and upper respiratory infections, serology, parasitology and fungal disease diagnosis. In addition, Meridian is a supplier of rare reagents, specialty biologicals and related technologies used by biopharmaceutical companies engaged in research for new drugs and vaccines. The Company markets its products and technologies to hospitals, reference laboratories, research centers, diagnostics manufacturers and biotech companies in more than 70 countries around the world. The Company's shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian's website address is www.meridianbioscience.com.
 GRAPHIC 3 image00005.jpg begin 644 image00005.jpg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ᠴ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end